Literature DB >> 33632820

Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies.

Che-Wei Chang1, Eric Shao1, Lennart Mucke2,3.   

Abstract

Several lines of evidence implicate the protein tau in the pathogenesis of multiple brain disorders, including Alzheimer's disease, other neurodegenerative conditions, autism, and epilepsy. Tau is abundant in neurons and interacts with microtubules, but its main functions in the brain remain to be defined. These functions may involve the regulation of signaling pathways relevant to diverse biological processes. Informative disease models have revealed a plethora of abnormal tau species and mechanisms that might contribute to neuronal dysfunction and loss, but the relative importance of their respective contributions is uncertain. This knowledge gap poses major obstacles to the development of truly impactful therapeutic strategies. The current expansion and intensification of efforts to translate mechanistic insights into tau-related therapeutics should address this issue and could deliver better treatments for a host of devastating conditions.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33632820      PMCID: PMC8118650          DOI: 10.1126/science.abb8255

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  150 in total

1.  Accelerated weight loss may precede diagnosis in Alzheimer disease.

Authors:  David K Johnson; Consuelo H Wilkins; John C Morris
Journal:  Arch Neurol       Date:  2006-09

2.  Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo.

Authors:  Sarah K Kaufman; David W Sanders; Talitha L Thomas; Allison J Ruchinskas; Jaime Vaquer-Alicea; Apurwa M Sharma; Timothy M Miller; Marc I Diamond
Journal:  Neuron       Date:  2016-10-27       Impact factor: 17.173

3.  Synaptogyrin-3 Mediates Presynaptic Dysfunction Induced by Tau.

Authors:  Joseph McInnes; Keimpe Wierda; An Snellinx; Laura Bounti; Yu-Chun Wang; Ilie-Cosmin Stancu; Nuno Apóstolo; Kris Gevaert; Ilse Dewachter; Tara L Spires-Jones; Bart De Strooper; Joris De Wit; Lujia Zhou; Patrik Verstreken
Journal:  Neuron       Date:  2018-02-01       Impact factor: 17.173

4.  Tau suppression in a neurodegenerative mouse model improves memory function.

Authors:  K Santacruz; J Lewis; T Spires; J Paulson; L Kotilinek; M Ingelsson; A Guimaraes; M DeTure; M Ramsden; E McGowan; C Forster; M Yue; J Orne; C Janus; A Mariash; M Kuskowski; B Hyman; M Hutton; K H Ashe
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

5.  Tau reduction prevents Abeta-induced defects in axonal transport.

Authors:  Keith A Vossel; Kai Zhang; Jens Brodbeck; Aaron C Daub; Punita Sharma; Steven Finkbeiner; Bianxiao Cui; Lennart Mucke
Journal:  Science       Date:  2010-09-09       Impact factor: 47.728

6.  Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model.

Authors:  Simantini Ghosh; Michael D Wu; Solomon S Shaftel; Stephanos Kyrkanides; Frank M LaFerla; John A Olschowka; M Kerry O'Banion
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

7.  Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice.

Authors:  Meaghan Morris; Patricia Hamto; Anthony Adame; Nino Devidze; Eliezer Masliah; Lennart Mucke
Journal:  Neurobiol Aging       Date:  2013-01-16       Impact factor: 4.673

8.  Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.

Authors:  Walter J Brecht; Faith M Harris; Shengjun Chang; Ina Tesseur; Gui-Qiu Yu; Qin Xu; Jo Dee Fish; Tony Wyss-Coray; Manuel Buttini; Lennart Mucke; Robert W Mahley; Yadong Huang
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

9.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.

Authors:  Sebastian Palmqvist; Shorena Janelidze; Yakeel T Quiroz; Henrik Zetterberg; Francisco Lopera; Erik Stomrud; Yi Su; Yinghua Chen; Geidy E Serrano; Antoine Leuzy; Niklas Mattsson-Carlgren; Olof Strandberg; Ruben Smith; Andres Villegas; Diego Sepulveda-Falla; Xiyun Chai; Nicholas K Proctor; Thomas G Beach; Kaj Blennow; Jeffrey L Dage; Eric M Reiman; Oskar Hansson
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

10.  A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity.

Authors:  Zeshan Ahmed; Jane Cooper; Tracey K Murray; Katya Garn; Emily McNaughton; Hannah Clarke; Samira Parhizkar; Mark A Ward; Annalisa Cavallini; Samuel Jackson; Suchira Bose; Florence Clavaguera; Markus Tolnay; Isabelle Lavenir; Michel Goedert; Michael L Hutton; Michael J O'Neill
Journal:  Acta Neuropathol       Date:  2014-02-16       Impact factor: 17.088

View more
  32 in total

1.  Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer's Disease.

Authors:  Marcel V Alavi
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2021-08-13       Impact factor: 4.739

2.  Functional Cooperation of α-Synuclein and Tau Is Essential for Proper Corticogenesis.

Authors:  Shengming Wang; Yu Fu; Takaki Miyata; Sakiko Matsumoto; Tomoyasu Shinoda; Kyoko Itoh; Akihiro Harada; Shinji Hirotsune; Mingyue Jin
Journal:  J Neurosci       Date:  2022-07-29       Impact factor: 6.709

3.  Tau target identification reveals NSF-dependent effects on AMPA receptor trafficking and memory formation.

Authors:  Emmanuel Prikas; Esmeralda Paric; Prita R Asih; Kristie Stefanoska; Holly Stefen; Thomas Fath; Anne Poljak; Arne Ittner
Journal:  EMBO J       Date:  2022-08-22       Impact factor: 14.012

4.  TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model.

Authors:  Eric Shao; Che-Wei Chang; Zhiyong Li; Xinxing Yu; Kaitlyn Ho; Michelle Zhang; Xin Wang; Jeffrey Simms; Iris Lo; Jessica Speckart; Julia Holtzman; Gui-Qiu Yu; Erik D Roberson; Lennart Mucke
Journal:  Sci Transl Med       Date:  2022-04-27       Impact factor: 19.319

5.  Alzheimer's disease: Ablating single master site abolishes tau hyperphosphorylation.

Authors:  Kristie Stefanoska; Mehul Gajwani; Amanda R P Tan; Holly I Ahel; Prita R Asih; Alexander Volkerling; Anne Poljak; Arne Ittner
Journal:  Sci Adv       Date:  2022-07-06       Impact factor: 14.957

6.  Loss of aly/ALYREF suppresses toxicity in both tau and TDP-43 models of neurodegeneration.

Authors:  Rebecca L Kow; Aristide H Black; Aleen D Saxton; Nicole F Liachko; Brian C Kraemer
Journal:  Geroscience       Date:  2022-02-04       Impact factor: 7.581

7.  Phenotypic Differences between the Alzheimer's Disease-Related hAPP-J20 Model and Heterozygous Zbtb20 Knock-Out Mice.

Authors:  Daniel R Gulbranson; Kaitlyn Ho; Gui-Qiu Yu; Xinxing Yu; Melanie Das; Eric Shao; Daniel Kim; Weiping J Zhang; Krishna Choudhary; Reuben Thomas; Lennart Mucke
Journal:  eNeuro       Date:  2021-05-13

Review 8.  Alzheimer's Disease-Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran.

Authors:  Klaus Grossmann
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 9.  Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Maroua Jalouli; Md Ataur Rahman; Philippe Jeandet; Tapan Behl; Athanasios Alexiou; Ghadeer M Albadrani; Mohamed M Abdel-Daim; Asma Perveen; Ghulam Md Ashraf
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

10.  ApoE and immunity in Alzheimer's disease and related tauopathies: Low-density lipoprotein receptor to the rescue.

Authors:  Andrew S Mendiola; Reshmi Tognatta; Zhaoqi Yan; Katerina Akassoglou
Journal:  Neuron       Date:  2021-08-04       Impact factor: 18.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.